- Home
- SRFM vs CMMB Comparison
SRFM vs CMMB Comparison
Compare SRFM & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- CMMB
- Stock Information
- Founded
- SRFM 2011
- CMMB 2004
- Country
- SRFM United States
- CMMB Israel
- Employees
- SRFM N/A
- CMMB N/A
- Industry
- SRFM Transportation Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- CMMB Health Care
- Exchange
- SRFM Nasdaq
- CMMB Nasdaq
- Market Cap
- SRFM 58.2M
- CMMB 23.0M
- IPO Year
- SRFM 2023
- CMMB N/A
- Fundamental
- Price
- SRFM $3.95
- CMMB $1.21
- Analyst Decision
- SRFM Buy
- CMMB Strong Buy
- Analyst Count
- SRFM 4
- CMMB 2
- Target Price
- SRFM $5.56
- CMMB $8.50
- AVG Volume (30 Days)
- SRFM 13.7M
- CMMB 186.3K
- Earning Date
- SRFM 08-13-2025
- CMMB 08-20-2025
- Dividend Yield
- SRFM N/A
- CMMB N/A
- EPS Growth
- SRFM N/A
- CMMB N/A
- EPS
- SRFM N/A
- CMMB N/A
- Revenue
- SRFM $112,307,000.00
- CMMB N/A
- Revenue This Year
- SRFM N/A
- CMMB N/A
- Revenue Next Year
- SRFM $54.32
- CMMB N/A
- P/E Ratio
- SRFM N/A
- CMMB N/A
- Revenue Growth
- SRFM 31.17
- CMMB N/A
- 52 Week Low
- SRFM $0.90
- CMMB $0.87
- 52 Week High
- SRFM $6.72
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- SRFM 64.64
- CMMB 37.38
- Support Level
- SRFM $3.30
- CMMB $1.17
- Resistance Level
- SRFM $4.16
- CMMB $1.22
- Average True Range (ATR)
- SRFM 0.79
- CMMB 0.06
- MACD
- SRFM 0.17
- CMMB -0.01
- Stochastic Oscillator
- SRFM 61.32
- CMMB 37.50
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.